- Home
- PETS vs BRNS Comparison
PETS vs BRNS Comparison
Compare PETS & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- BRNS
- Stock Information
- Founded
- PETS 1996
- BRNS 2016
- Country
- PETS United States
- BRNS United Kingdom
- Employees
- PETS N/A
- BRNS N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- BRNS Health Care
- Exchange
- PETS Nasdaq
- BRNS Nasdaq
- Market Cap
- PETS 53.7M
- BRNS 58.0M
- IPO Year
- PETS N/A
- BRNS 2021
- Fundamental
- Price
- PETS $2.54
- BRNS $1.61
- Analyst Decision
- PETS Sell
- BRNS Strong Buy
- Analyst Count
- PETS 1
- BRNS 1
- Target Price
- PETS $3.20
- BRNS $3.00
- AVG Volume (30 Days)
- PETS 113.6K
- BRNS 248.2K
- Earning Date
- PETS 11-05-2025
- BRNS 11-05-2025
- Dividend Yield
- PETS N/A
- BRNS N/A
- EPS Growth
- PETS N/A
- BRNS N/A
- EPS
- PETS 0.02
- BRNS N/A
- Revenue
- PETS $247,010,000.00
- BRNS $14,969,000.00
- Revenue This Year
- PETS N/A
- BRNS N/A
- Revenue Next Year
- PETS N/A
- BRNS N/A
- P/E Ratio
- PETS $148.85
- BRNS N/A
- Revenue Growth
- PETS N/A
- BRNS 1766.46
- 52 Week Low
- PETS $2.45
- BRNS $0.64
- 52 Week High
- PETS $6.85
- BRNS $2.92
- Technical
- Relative Strength Index (RSI)
- PETS 36.72
- BRNS 65.26
- Support Level
- PETS $2.52
- BRNS $1.36
- Resistance Level
- PETS $2.64
- BRNS $1.67
- Average True Range (ATR)
- PETS 0.09
- BRNS 0.17
- MACD
- PETS 0.01
- BRNS 0.05
- Stochastic Oscillator
- PETS 23.75
- BRNS 72.15
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.